Søgning på udtrykket 'hiv' giver 163 resultater
Dokumenter [17]
Sider [7]
Kalender [90]
Nyt fra tidsskrifterne [+20]
Aktuelle smitsomme sygdomme [+20]
Dokumenter [17]
Forfattere: Jan Gerstoft, Nina Weis, Terese L. Katzenstein (Dansk Selskab for Infektionsmedicin), Anders Nyboe Andersen og Jens Fedder (Dansk Fertilitetsselskab).
Version: 3. Endelig guideline: 01.09.2020. Guideline skal revideres senest: 01.09.2023
Arbejdsgruppens medlemmer: Peer Brehm Christensen, Christian Erikstrup, Jan Gerstoft, Terese Katzenstein, Alex Laursen, Suzanne Lunding, Birgitte Mørn og Nina Weis.
Arbejdsgruppen bestod af: Jan Gerstoft, Ann-Brit Eg Hansen, Gitte Kronborg, Jens D. Lundgren, Henrik I. Nielsen, Olav Ditlevsen Larsen, Niels Obel og Alex Laursen
Fællesregional retningslinje for udlevering af forebyggende medicin mod HIV (PrEP), udgivet af Danske Regioner.
medicin i form af f.eks TNF-α hæmmere eller andre immunsupprimerende biologiske lægemidler, hvor der er øget risiko for tuberkulosereaktivering.
Guideline dækker ikke børn, personer med medfødt immundefekt, HIV positive, patienter i dialyse, patienter med dysreguleret diabetes, silicose, erhvervede immundefekter eller patienter i konventionel kortvarig kemoterapi.
Denne guideline omhandler ikke klassisk smitteopsporing blandt tuberkuloseeksponerede eller udredning på mistanke om aktiv tuberkulose.
r (BMSL) til patienter i forhold til risiko for tuberkulose (TB), Humant Papillom Virus (HPV), Hepatitis B og C (HBV og HCV), Varicella Zoster Virus (VZV), Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) og Humant Immundefekt Virus (HIV) og øvrige infektioner.
Vejledningen er udarbejdet af repræsentanter fra Dansk Selskab for Gastroenterologi og Hepatologi (DSGH), Dansk Reumatologisk Selskab (DRS), Dansk Dermatologisk Selskab (DDS) og Dansk Selskab for Infektionsmedicin (DSI).
Revideret september 2020. Arbejdsgruppen bestod af Suzanne Lunding (formand), Peer Brehm Christensen, Christian Erikstrup, Terese L. Katzenstein, Henrik Krarup, Alex Lund Laursen, Birgitte Mørn og Nina Weis
Udarbejdet af DSI's arbejdsgruppe vedrørende antiretroviral terapi
Arrangeret af Yngre Infektionsmedicinere
Correspondence regarding "Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy"
Henvendelse til Danske regioner
Senest revideret september 2021 . Arbejdsgruppen bestod af: Jan Gerstoft, Gitte Kronborg , Ann Brit Eg Hansen, Jens D. Lundgren, Henrik I. Nielsen, Olav Ditlevsen Larsen , Niels Obel og Alex Laursen
Forfattet af DSI's arbejdsgruppe vedrørende antiviral behandling
Bilag til Retningslinjer for screening og profylakse før behandling med biologiske lægemidler (2023)
Sider [7]
Formål:
At kursisten skal opnå en forståelse af HIV-infektionen herunder viden om dens epidemiologi, patogenese, patofysiologi, diagnose, forebyggelse, behandlingsmuligheder og prognose samt viden om diagnostik og behandlingen af AIDS-definerende sygdomme og de hyppigste sexuelt overførte sygdomme.
Tid og sted:
Hvidovre Hospital. Lokale 10 i undervisningsbygningen.
Delkursusledere:
Ann-Brit Eg Hansen og Ole Kirk.
Program:
Mandag 3. oktober:
10:00-10:15 Velkomst og introduktion (Ann-
me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co
epatitis:
Carsten Shade Larsen og Nina Weis.
Hepatitis A (2013),
Antiretroviral terapi:
Henrik Nielsen, Jan Gerstoft, Jens Lundgren, Alex Laursen, Niels Obel, Isik Somuncu, Gitte Kronborg, Ann-Brit Eg Hansen
Antiviral behandling af hiv smittede personer (2021),
Fertilitetsbehandling ved HIV og hepatitis B og C (2018),
HIV behandling af gravide (2021),
HIV post exposure profylakse (2020),
Pre-exposure profylakse mod HIV (2021),
Borrelia:
Anne-Mette Lebech (tovho
terologiske infektioner og kronisk hepatitis:
Dato for næste kursus
2026:
Sted
Odense Universitetshospital
Delkursusledelse
Lone Mygind, Micha Jepsen og Belinda Mössner
Tidligere kurser
4. og 5. december 2023
3. og 4. december 2020
HIV-infektion:
Næste kursus
Efterår 2025 (2 dage):
Sted
Afventer
Delkursusledelse
Ole Schmeltz Søgaard og Lene Ryom Nielsen
Program
Afventer
Tidligere kurser
12. og 13. oktober 2022
7. og 8. oktober 2019
3. og 4. oktober 2016
me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co
iklen summerer på en rimelig afbalanceret måde den globale kontrovers, som 2013 var præget af, om hvorvidt ART skal benyttes som forebyggende middel, som led i en individuel-baseret eller en folkesundsbaseret strategi for at reducere smittespredning af HIV. De udfordringer som den vestlige verden, trods udbredt og gratis behandlingstilbud, har med at få styr på smittespredning blandt fx mænd-der-har-sex-med-mænd viser, at det - der intuitivt synes ligefor - ikke nødvendigvis virker når det kommer t
Professor Henrik Nielsen kommenterer: Trods indiskutable fremskridt i den farmakologiske behandling af HIV/AIDS er der fortsat områder med plads til forbedring.
Blandt patienter i kronisk behandling er HAND (HIV-associated neurocognitive disorder) et af disse eksempler. Det har været debatteret om forskelle i antiretrovirale lægemidlers penetrans over blod/hjerne barrieren har betydning for HAND og for AIDS-definerende opportunistisk infektion i hjernen.
Der er ingen tvivl om at koncentr
Professor Jens Lundgren kommenterer: I 2014 var verden optaget af Ebola udbruddet i Vest Afrika – et udbrud der blev erkendt hurtigt (om end den internationale assistance lod vente på sig).
Vedlagte artikel belyser detaljeret hvorledes HIV pandemien startede i 1920’erne og hvor det jo som bekendt tog over 60 år af finde ud at der overhovedet var et problem.
Synes artiklen er godt skrevet og giver et indblik i Afrika for 90 års siden og de ingredienser der skulle til for at ud
Professor Lars Østergaard kommenterer: Jeg vil gerne anbefale vedlagte artikel som julemånedslæsning. Grundene er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor. 3) Det er den første originalartikel trykt i den
Professor Jens Lundgren kommenterer: I 2015 nåede WHO sit mål om at få 15 million på behandling. START studiet afklarede også at alle HIV+ personer har gavn af at starte på HIV behandling. Der er fortsat mere end 20 millioner der endnu ikke er startet. Hovedparten bor i ressource svage lande hvor adgang til monitorering af HIV mængden er begrænset og behandlingsskift pga behandlingssvigt er derfor primært drevet af klinik og CD4 tals måling. Omkostning ifm nyttevirkning er central i at forbedre be
dolutegravir, især når det kombineres med TAF fremfor tenofovir DF, forårsager markant vægtøgning. Især hos kvinder med mørk hudfarve. Artiklen gør indtryk af en række grunde:. Da dolutegravir blev markedsført havde det profilen som det eneste HIV præparat uden bivirkninger. Læring: der er ingen medicinske præparater der ikke har nogle bivirkninger, og typen af bivirkninger kan ikke altid forudsiges udfra markedsføringsstudier (fase I-III). Dette faktum er universelt og set for praktisk tage
Professor Jens Lundgren kommenterer: Første lægemiddel mod SARS-CoV-2 udviklet fra ”bunden” – bruger et gammel trick fra HIV medicinen (ritonavir) for at holde plasma koncentrationerne oppe. Læringen er, at det tager tid at lave nye lægemidler helt fra bunden, men det er noget nær en verdensrekord så hurtigt som det skete under pandemien – både hvad angår vacciner (hvor det tog < 1 år fra design ex vivo til markedsføring), men altså ca 2 år for lægemidler som dette.
Professor Lars Østergaard kommenterer: Indimellem kommer der studier, som er så overbevisende, at det sætter en ny behandlingsstandard.
Det kan f.eks. være Lundgrens studie af, hvornår man kan holde op med at give pneumocyste-profylakse til HIV-smittede eller de Gans studiet, der ændrede fik indført dexamethason i retningslinjerne for purulent meningitis.
Her er formentlig et nyt studie, der kommer til at få indflydelse på standardbehandlingen af patienter med svær pneumoni.
Læs en gang - og d
Professor Troels Lillebæk kommenterer: Interessant systematisk review i AIDS om udbytte af screening for tuberkulose infektion (TBI) blandt personer, der lever med HIV (PLHIV) i tuberkulose lav-incidens lande (som Danmark) . Inddraget i alt 51 undersøgelser med 65.930 PLHIV hvoraf 12 % havde en positiv LTBI-test, som var stærkt relateret til oprindelsesland og eksponering for TB ). Forfatterne beretter at 20 TBI-positive personer skulle behandles for at forhindre ét tilfælde af TB, og at antallet, der
Kalender [90]
27. oktober, Glasgow, Skotland
27. september 2023, Stockholm, Sverige
24. august 2023, Emil Aarestrup Auditorium, Odense Universitetshospital
23. juli 2023, Brisbane, Australien og virtuelt
7. juni 2023, Rom, Italien
1. juni 2023, Mærsk Tårnet, Panum Instituttet, København
10. maj 2023, Avignon, Frankrig
27. januar 2023, Karen Brahe auditoriet, Odense Adelige Jomfrukloster (og online)
14. december 2022, Statens Institut for Folkesundhed og online
23. oktober 2022, Glasgow, Skotland
20. oktober 2022, Washington DC, USA
12. oktober 2022, Hvidovre Hospital
28. september 2022, Stockholm, Sverige
22. september 2022, Barcelona, Spanien
10. juni 2022, Panum, København
17. maj 2022, Niels K. Jerne auditoriet, Panum Instituttet, København
10. maj 2022, Avignon, Frankrig
6. december 2021, Rigshospitalet
26. november 2021, Panum, København
30. september 2021, Barcelona, Spanien
18. juli 2021, Berlin, Tyskland
28. oktober 2020, Paris, Frankrig
25. oktober 2020, Glasgow, Skotland
28. august 2020, Online og Henrik Dam auditoriet, Maersk Tårnet
10. marts 2020, KolleKolle, Værløse
7. oktober 2019, København
11. september 2019, DGI-byen, København
21. juli 2019, Mexico City, Mexico
22. maj 2019, Rom, Italien
13. maj 2019, København, Odense, Aarhus
6. marts 2019, KolleKolle, Værløse
2. november 2018, Mærsk Tower, København
28. oktober 2018, Glasgow, Skotland
30. maj 2018, Rom, Italien
16. maj 2018, Marseille, Frankrig
4. maj 2018, Hindsgavl, Middelfart
28. februar 2018, Nielsine Nielsen Auditorium, Mærsk Tårnet, København
23. februar 2018, Syddansk Universitet, Odense
1. februar 2018, Nielsine Nielsen auditoriet, Mærsk Tårnet, København
6. oktober 2017, Holst Auditoriet, Mærsk tårnet, København
8. juni 2017, Hvidovre Hospital
4. maj 2017, Odense Universitetshospital
18. april 2017, Auditorium 93, Rigshospitalet
23. oktober 2016, Glasgow, Skotland
3. oktober 2016, Hvidovre Hospital
18. september 2016, Brisbane, Australien
25. maj 2016, Rom, Italien
29. april 2016, Hindsgavl, Middelfart
7. januar 2016, Medicinsk Museion, København
18. december 2015, Emil Aarestrup auditorium, Odense Universitetshospital
24. november 2015, Hvidovre Universitetshospital
8. september 2015, Panum Instituttet, København
18. juni 2015, Rigshospitalet, Teilum B
12. juni 2015, Medicinsk Museion, København
3. juni 2015, Barcelona, Spanien
24. april 2015, Auditorium 93, Rigshospitalet
17. april 2015, Foredragssalen, Statens Serum Institut
19. marts 2015, Auditorium 1, Rigshospitalet
2. november 2014, Glasgow, Skotland
5. oktober 2014, Barcelona, Spanien
5. juli 2014, Sigtuna, Sverige
18. juni 2014, Store Auditorium, Winsløwparken 15, st., 5000 Odense C
22. april 2014, Auditorium 5, Hvidovre Hospital
26. marts 2014, Barcelona, Spanien
20. februar 2014, Rigshospitalet
25. oktober 2013, Hannover auditoriet, Panum Instituttet, København
30. juni 2013, Kuala Lumpur, Malaysia
10. juni 2013, Centre for Medical Parasitology, København
3. maj 2013, Hindsgavl, Fyn
20. marts 2013, Rom, Italien
3. marts 2013, Atlanta, Georgia, USA
14. januar 2013, Auditorium 2, Rigshospitalet
10. november 2012, Auditorium 2, Rigshospitalet
25. oktober 2012, Danmarks Medie- og Journalisthøjskole
23. oktober 2012, Rigshospitalet
2. oktober 2013, San Francisco, USA
27. september 2012, Auditorium 1, Bartholinbygningen, bygning 1241, lokale 135, Aarhus Universitet
29. februar 2012, SSI, København
9. december 2011, Rigshospitalet, københavn
7. november 2011, Auditorium 93, Rigshospitalet
13. maj 2011, Panum instituttet, København
29. april 2011, Auditorium B, Skejby
12. april 2011, Auditorium 100, Campusvej 55, 5230 Odense M, Syddansk Universitet
30. november 2007, Panum Instituttet, København
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
BMJ Open
19.03.2024
. Introduction. Young people aged 18–24 years old are a key demographic target for eliminating HIV transmission globally. Pre-exposure prophylaxis (PrEP), a prevention medication, reduces HIV transmission. Despite good uptake by gay and bisexual men who have sex with men, hesitancy to use PrEP has been observed in other groups, such as young people and people from ethnic minority backgrounds. The aim of this study was to explore young people’s perceptions and attitudes to using PrEP. . Design. A qualit
BMC Infectious Diseases
18.03.2024
. Abstract. . Background. Our aim was to examine the prevalence and characteristics of difficult-to-treat HIV in the current Swedish HIV cohort and to compare treatment outcomes between people with difficult and non-difficult-to-treat HIV. . . . Methods. In this cross-sectional analysis of the Swedish HIV cohort, we identified all people wit
Infection
16.03.2024
. Abstract. . Purpose. The risk of developing active tuberculosis (TB) is considerably increased in people living with HIV/AIDS (PLWH). However, incidence of HIV/TB coinfection is difficult to assess as surveillance data are lacking in many countries. Here, we aimed to perform a quantitative analysis of HIV/TB coinfections within the Cologne/Bonn HIV cohort and to determine risk factors for active TB. . .
Clinical Infectious Diseases
16.03.2024
Abstract . Background . Oral pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) has high efficacy against HIV-1 acquisition. Seventy-two prospective studies of daily oral F/TDF PrEP were conducted to evaluate HIV-1 incidence, drug resistance, adherence, and bone and renal safety in diverse settings.Methods . HIV-1 incidence was calculated from incident HIV-1 diagnoses after PrEP initiation and within 60 days of discontinuation. Tenofovir concentration in dried blood spo
PLoS One Infectious Diseases
15.03.2024
by Rumbidzai Chireshe, Tawanda Manyangadze, Keshena Naidoo . Background Integrated health care is an approach characterized by a high degree of collaboration and communication among health professionals. Integration of HIV/NCD is recommended to enhance the quality of healthcare services being provided. Duplication of limited resources is minimized, and a holistic care approach is promoted by shifting from acute and reactive care to care that embraces patient-centredness that includes promotive health and d
Journal of Acquired Immune Deficiency Syndromes
15.03.2024
Background: . We compared HIV care outcomes by HIV provider type to inform efforts to strengthen the HIV provider workforce. Setting: . U.S. Methods: . We analyzed data from CDC’s Medical Monitoring Project collected during 6/2019-5/2021 from 6,323 adults receiving HIV medical care. Provider types were infectious disease physicians only (ID physicians), non-ID physicians only (non-ID physicians), nurse practitioners only (NPs), physician assistants only (PAs), and ID physicians plus NPs and/or PAs (mix
Journal of Acquired Immune Deficiency Syndromes
15.03.2024
Background: . Postpartum weight (PPW) contributes to long-term obesity, a growing concern in persons with HIV (PWH). We investigated whether inflammatory markers in pregnancy may be involved in postpartum (PP) obesity in PWH. Setting: . A total of 57 pregnant PWH enrolled at ≤14 weeks gestation (T1) in Gugulethu antenatal care clinic in Cape Town and followed through 48 weeks PP were included. Methods: . Plasma soluble (s) CD14, sCD163, leptin, tumour necrosis factor receptor 1 (TNFR-1), resistin, adip
Journal of Acquired Immune Deficiency Syndromes
15.03.2024
Background: . People who live with HIV (PWLH) have been one of the most affected groups during the current mpox outbreak. They are hypothesized to have a more severe clinical course than people without HIV but comparative data is scarce. We aimed to compare clinical features and outcomes of mpox in people with and without HIV in Mexico. Setting: . Country-wide study in Mexico. Methods: . We performed an observational study using nation-wide epidemiological data. We included all people with confirmed mpox
BMC Infectious Diseases
15.03.2024
. Abstract. . Introduction. In 2022, the WHO reported that 29.8 million people around the world were living with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people in Gabon (54% of all those living with HIV in the country). The literature reports a frequency of therapeutic failure with first-line antiretrovirals (ARVs) of between 20% and 82%. Unfortunately, data relating to the failure of s
Antimicrobial Agents And Chemotherapy
14.03.2024
Antimicrobial Agents and Chemotherapy, Ahead of Print.
BMC Infectious Diseases
14.03.2024
. Abstract. . Background. Availability and accessibility of Antiretroviral drugs (ARV’s) improve the lives of People living with HIV (PLHIV) by improving client’s immune system to overcome infections and prevent the development of AIDS and other HIV complications. Combination therapy, early initiation of ART, newer ART drugs, single dosage and drug affordability significantly contribute in the reduction of viral multipli
BMJ Open
14.03.2024
. Objectives. In 2015 and 2016, WHO issued guidelines on HIV testing services (HTS) highlighting recommendations for a strategic mix of differentiated HTS approaches. The policy review examines the uptake of differentiated HTS approaches recommendations in national policies. . Methods. Data were extracted from national policies published between January 2015 and June 2019. The WHO-recommended HTS approaches included facility-based testing, community-based testing, HIV self-testing and provider-assisted ref
PLoS One Infectious Diseases
14.03.2024
de B. M. Filho, Maria de Fátima P. M. Albuquerque, Heloísa R. Lacerda, George T. N. Diniz, Ulisses R. Montarroyos, Laura C. Rodrigues, Líbia Cristina R. Vilela Moura, Ricardo A. A. Ximenes . Background The CD4 T lymphocyte count in people living with HIV (PLHIV) is a predictor for the progression of the disease (AIDS), survival and response to antiretroviral treatment (ART). A CD4 T lymphocyte count of less than 200 cells/mm3 is indicative of a greater risk for the onset of opportunistic diseases and d
Journal of Medical Virology
13.03.2024
Journal of Medical Virology, Volume 96, Issue 3, March 2024.
BMJ Open
13.03.2024
. Introduction. Oral pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention method; however, uptake and persistence have been low among southern African women. A dual prevention pill (DPP) that combines PrEP with oral contraception (OC) may increase PrEP use and better meet women’s sexual and reproductive health needs. We will gauge the DPP’s acceptability in two cross-over clinical trials. . Methods and analysis. PC952 (Zimbabwe) and PC953 (South Africa) will compare acceptability, adher
BMC Infectious Diseases
12.03.2024
. Abstract. . Background. In Malawi, female sex workers (FSW) have high HIV incidence and regular testing is suggested. HIV self-testing (HIVST) is a safe and acceptable alternative to standard testing services. This study assessed; whether social harms were more likely to be reported after HIVST distribution to FSW by peer distributors than after facility-based HIV testing and whether FSW regretted HIVST use or experienced
Journal of Infectious Diseases
12.03.2024
Abstract . Background . The association between low-frequency HIV-1 drug resistance mutations (DRMs) and treatment failure (TF) is controversial. We explore this association using NGS methods that accurately sample low-frequency DRMs.Methods . We enrolled women with HIV-1 in Malawi who were either ART naïve (A), had ART failure (B), or had discontinued ART (C). At entry, A and C began an NNRTI-based regimen and B started a PI-based regimen. We used Primer ID MiSeq to identify regimen-relevant DRMs in entry
BMC Infectious Diseases
12.03.2024
. Abstract. . Background. In Malawi, female sex workers (FSW) have high HIV incidence and regular testing is suggested. HIV self-testing (HIVST) is a safe and acceptable alternative to standard testing services. This study assessed; whether social harms were more likely to be reported after HIVST distribution to FSW by peer distributors than after facility-based HIV testing and whether FSW regretted HIVST use or experienced
Journal of Acquired Immune Deficiency Syndromes
8.03.2024
Background: . Non-acquired immunodeficiency syndrome (AIDS)-defining cancers (NADCs) in patients infected with human immunodeficiency virus (HIV) have recently attracted attention because of the improved survival of this patient population. To obtain accurate data, a longitudinal study is warranted for the nationwide surveillance of the current status and national trend of NADCs in patients infected with HIV in Japan. Setting: . An annual nationwide surveillance of NADCs in patients infected with HIV-1 in
Journal of Acquired Immune Deficiency Syndromes
8.03.2024
Background: . Earlier antiretroviral therapy (ART) may decrease progression to advanced HIV disease (AHD) with CD4
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
Eurosurveillance latest updates
15.03.2024
. Background. Some migrant men who have sex with men (MSM) acquire HIV in France. . . Aims. We investigated, in migrant MSM receiving HIV care in France, the (i) rate of post-migration-HIV acquisition in France, (ii) delay between arrival and HIV acquisition and (iii) factors affecting HIV acquisition within 1 year after migration. . . Methods. This cross-sectional study focused on ≥ 18-year-old MSM born outside France, receiving HIV care in the Paris region. Information on migration history,
Medscape Infectious Diseases
11.03.2024
Semaglutide improved MASLD in this population, and weight loss associated with its use resulted in no significant changes in physical function, according to two presentations at CROI. . Medscape Medical News
Medscape Infectious Diseases
8.03.2024
A nurse-led multicomponent strategy significantly reduced systolic blood pressure and non-HDL cholesterol in HIV patients and should be included in HIV primary care programs. . Medscape Medical News
Medscape Infectious Diseases
6.03.2024
The World Health Organization (WHO) said on Tuesday resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its trials, citing observational and survey. . Reuters Health Information
Medscape Infectious Diseases
5.03.2024
The last attempt in a generation of HIV vaccine development ended in disappointment, but investigators are starting over because they believe the human body can make antibodies for HIV. . Medscape Medical News
Medscape Infectious Diseases
5.03.2024
President Joe Biden's administration on Monday urged a U.S. appeals court to preserve a federal mandate that requires health insurers to cover preventive care services. . Reuters Health Information
Medscape Infectious Diseases
28.02.2024
British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment,. . Reuters Health Information
Medscape Infectious Diseases
26.02.2024
The smallpox vaccine effectively induces immunity against mpox virus infection in patients with HIV, although patients with low lymphocyte counts require booster doses. . Medscape Medical News
Eurosurveillance latest updates
9.02.2024
is in immunodeficient (ID) individuals are scarce. This population may present with atypical clinical symptoms, be infected by uncommon pathogens and develop poor outcomes. . . Aim. We aimed to describe the epidemiology of infectious encephalitis among HIV-negative ID patients. . . Methods. Patients from the ENCEIF (Etude Nationale de Cohorte des Encéphalites Infectieuses en France) prospective cohort meeting criteria for infectious encephalitis between January 2016 and December 2019 were included. W
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report examines the relationship between structural and psychosocial syndemic conditions and condomless anal intercourse among Black, White, and Hispanic transgender women from seven urban areas in the U.S.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report describes the association between experiences of certain forms of violence and harassment and suicidal ideation among transgender women and explores the moderation of the association by perceived social support.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report describes the prevalence of six discrimination types toward transgender women and the association between employment discrimination and sociodemographic characteristics, health care access, and health care use.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report identifies specific personal characteristics and social factors associated with the duration of homelessness among transgender women from seven urban areas in the U.S.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This analysis explored demographic, health care, and economic correlates of nonprescription hormone use among transgender women from seven urban areas in the U.S.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report examines whether transgender women who report behaviors associated with HIV acquisition were more likely to have had discussions with their clinician about pre-exposure prophylaxis (PrEP) and used PrEP.
Morbidity and Mortality Weekly Report (MMWR)
26.01.2024
This report describes 2019-2020 data and system methods from the National HIV Behavioral Surveillance Among Transgender Women.
Medscape Infectious Diseases
11.01.2024
New findings support starting tecovirimat treatment at the time of suspected mpox diagnosis in all people with HIV. . MDedge News
Medscape Infectious Diseases
1.12.2023
At least 450 patients at Mass General Brigham, Salem Hospital, near Boston are at risk of HIV and hepatitis infection, according to a lawsuit claiming negligent intravenous medication administration. . Medscape Medical News
Medscape Infectious Diseases
1.12.2023
Europe's advances in HIV prevention strategies, including PrEP and long-acting retrovirals, bring hope amidst persistent access challenges and disparities. . Medscape Medical News
Eurosurveillance latest updates
1.12.2023
. Background. The global distribution of HIV-1 subtypes is evolving, which is reflected in the Swedish HIV cohort. The subtype HIV-1A6, which may be prone to developing resistance to cabotegravir, is the most common subtype in Ukraine. . . Aim. We aimed to examine trends in HIV-1 subtype distribution in Sweden, with a special focus on HIV-1A6, and to describe the virology, demography and treatment of Ukrainian people living with HIV (PLWH) who migrated to Sweden in 2022. . . Methods. Data about PLWH in